FDA lifts hold on Achillion's hepatitis C drug, shares jump

June 10, 2014 12:40 PM

6 0

FDA lifts hold on Achillion's hepatitis C drug, shares jump

(Reuters) - Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago.

The U.S. health regulator placed a hold on the development of the drug, sovaprevir, in July last year after data from an early-stage study showed elevated liver enzymes - a sign of liver damage - in some patients who received the drug.

Also read: FDA approves Bayer's Stivarga to treat most common liver cancer

Read more

To category page

Loading...